Canakinumab as Adjuvant Therapy in Patients With Completely ...

CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with resected, stage II-III NSCLC.

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

... canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients ... Canakinumab as Adjuvant Therapy in Patients With Completely ...

MO01.22 Canakinumab as Adjuvant Therapy in Patients with ...

In the CANTOS study, canakinumab treatment was associated with reduced incidence and mortality from NSCLC in patients with stable post-myocardial infarction ...

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, ...

Abstract CT255: Canakinumab as adjuvant therapy in patients with ...

Abstract. Background: In the CANTOS study, canakinumab (selective interleukin 1β inhibitor) treatment was associated with reduced incidence ...

Canakinumab as Adjuvant Therapy in Patients With Completely ...

CONCLUSION CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with ...

LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as ...

LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).

Abstract LBA039: Canakinumab as Adjuvant Therapy in Patients ...

Abstract. Background: In the CANTOS study, canakinumab (selective interleukin 1β inhibitor) treatment was associated with reduced incidence ...

Adjuvant Canakinumab in Completely Resected NSCLC

Garon, MD, and colleagues found that adjuvant therapy with the interleukin (IL)-1β pathway inhibitor canakinumab did not significantly improve ...

Canakinumab as Adjuvant Therapy in Patient - ATS Journals

Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer: CANOPY-A Trial. A. Spira1, A. Ardizzoni2, F. Barlesi3, B ...

Novartis provides update on Phase III CANOPY-A study evaluating ...

These positive signals supported the study of canakinumab as adjuvant treatment for early lung cancer,” said Jeff Legos, Executive Vice ...

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Request PDF | Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non–Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, ...

Lack of clinical benefit with adjuvant canakinumab in completely ...

The phase III CANOPY-A trial evaluated canakinumab (200 mg), as adjuvant therapy in patients with completely resected NSCLC who had received ...

LBA49 CANOPY-A - Annals of Oncology

CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC). E.B. Garon1 ...

a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients ...

Related trials · PD01. · CANOPY-A: a phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC.

Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in ...

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical ...

Adjuvant Canakinumab Misses DFS Primary End Point in NSCLC

Patients with completely resected non–small cell lung cancer did not derive a significant benefit with adjuvant canakinumab vs placebo.

CANOPY-A Trial - Journal of Thoracic Oncology

Capmatinib was well tolerated in post IO patients. MO01.22. Canakinumab as Adjuvant Therapy in Patients with. Completely Resected Non-Small Cell Lung Cancer. ( ...

Canakinumab Fails to Improve DFS in Resected NSCLC

Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely ...

Canakinumab adjuvant therapy for treating completelyresected non ...

Canakinumab is in clinical development as an adjuvant therapy for stage II-III non-small cell lung cancer (NSCLC) that has been surgically completely ...